The PubMed record reports the PSMAddition trial as a phase 3, randomised, controlled trial of [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator‑naive/sensitive prostate cancer, as reflected in the article title. The entry on PubMed identifies the report as published in Lancet with the citation details provided below. The PubMed excerpt available here contains bibliographic metadata, author and affiliation listings, and links to full-text options but does not present trial results or detailed methods in the visible excerpt.
Information explicit in the PubMed title and record:
No additional trial design elements (for example, control intervention, primary or secondary endpoints, randomisation ratio, stratification factors, or duration of follow-up) are reported in the PubMed excerpt available here. The PubMed entry does not include the abstract text in the provided clip, so protocol specifics, eligibility criteria, dosing regimen, imaging or biomarker requirements, and statistical analysis plans are not reported in this source excerpt.
The PubMed record lists a large, multinational author group and collaborating sites. Lead and contributing authors named in the entry include Scott T Tagawa and Michael J Morris among many others. Affiliations cover academic medical centers and hospitals across multiple countries, including institutions in the USA, Canada, several European countries, South Korea, Taiwan, and China. Authors with industry affiliations (Novartis Pharmaceuticals) are also included in the listed author group.
The PubMed entry supplies institutional affiliations for many authors and identifies the group collectively as the PSMAddition Investigators. No author contributions, funding statements, or conflict of interest details are included in the excerpt shown here; the PubMed page does show a navigation link to a conflict of interest statement but that content is not included in the clipped material.
The bibliographic data shown on PubMed are:
A full-text link to Elsevier/Lancet is visible from the PubMed record. The entry is indexed as a Clinical Trial on PubMed.
Reported in this PubMed excerpt:
Omitted from the provided PubMed excerpt (not available in the clipped content):
Because these critical trial elements and outcomes are not contained in the PubMed excerpt provided, the present summary does not include any efficacy, safety, or conclusion statements; those would need to be taken directly from the Lancet full text or the complete PubMed abstract.
The PubMed entry provides the DOI (10.1016/S0140-6736(26)01092-5) and a direct link to Elsevier/Lancet full-text options from the PubMed page. To review trial methods, results, statistical analyses, and authors' conclusions, consult the Lancet full-text article or the complete PubMed abstract. The PubMed record also lists the PMID (42561994) for citation and retrieval.
Note on source limitations
This editorial rewrite is strictly based on the PubMed record excerpt supplied as the source of truth. That excerpt supplies title, author list, affiliations, journal citation, DOI, and PMID but does not include abstract content, methods, numerical results, or conclusions. Any reader seeking outcome data, safety information, or practical clinical implications must consult the full Lancet publication or the complete PubMed abstract; such data were not reported in the source excerpt used here.